Filing Details
- Accession Number:
- 0001209191-17-047139
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-08-02 16:56:58
- Reporting Period:
- 2017-07-31
- Filing Date:
- 2017-08-02
- Accepted Time:
- 2017-08-02 16:56:58
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1242825 | M Jeffrey Leiden | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Ceo & President | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-07-31 | 11,063 | $45.11 | 268,455 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-07-31 | 5,363 | $152.25 | 263,092 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2017-07-31 | 5,000 | $153.24 | 258,092 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2017-07-31 | 700 | $154.05 | 257,392 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2017-07-31 | 11,063 | $0.00 | 11,063 | $45.11 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 55,313 | 2023-02-04 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 440 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $152.25 (range $151.79 to 152.77).
- Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $153.24 (range $152.79 to $153.78).
- Open market sales reported on this line occurred at a weighted average price of $154.05 (range $153.91 to $154.27).
- Fully vested.
Billionaire Hedge Funds
